To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.

European Endocrinology Highlights Diabetes 20. Hinman RM1, Cambier JC, Role of B lymphocytes in the pathogenesis of type 1 diabetes, Curr Diab Rep, 2014;14:543. 21. Pescovitz MD , Greenbaum CJ, Krause-Steinrauf H, et al., Rituximab, B-lymphocyte depletion, and preservation of beta-cell function, N Engl J Med, 2009;361:2143–52. 22. Pescovitz MD, Greenbaum CJ, Bundy B, et al., B-lymphocyte depletion with rituximab and β-cell function: two-year results, Diabetes Care, 2014, 37:453-9. 23. Roncarolo MG, Zoppo M, Bacchetta R, et al., Interleukin-2 production and interleukin-2 receptor expression in children with newly diagnosed diabetes, Clin Immunol Immunopathol, 1988;49:53–62. 24. Tang Q, Adams JY, Penaranda C, central role of defective interleukin-2 production in the triggering of islet autoimmune destruction, Immunity, 2008;28:687–97. 25. Grinberg-Bleyer Y, Baeyens A, You S, et al., IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells, J Exp Med, 2010;207:1871-8. 26. Hartemann A, Bensimon G, Payan CA, et al., Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial, Lancet Diabetes Endocrinol, 2013;1:295-305. 27. National Institute of Diabetes and Digestive and Kidney Diseases, European Phase-IIb Clinical Trial Evaluating Efficacy of Low Dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes DIABIL-2. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2015. Available at: https://clinicaltrials.gov/ ct2/show/NCT02411253 NLM Identifier: NCT02411253 (accessed 8 May 2016). 28. Waldron-Lynch F, Kareclas P, Irons K, Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial, BMJ Open, 2014;4:e005559. 29. University of British Columbia, Phase I/II Study of Ustekinumab in Patients With New-onset Type 1 Diabetes. In: ClinicalTrials. gov [Internet]. Bethesda, MD, National Library of Medicine, 2014. Available at: https://clinicaltrials.gov/ct2/show/ NCT02117765 NLM Identifier: NCT02117765 (accessed 8 May 2015). 30. Jewish General Hospital, A Single-center, Open-Label, Exploratory Study to Assess the Tolerability and Safety of the Addition of Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With Type 1 Diabetes Mellitus. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2014. Available at: https://clinicaltrials.gov/ct2 /show/NCT02204397 NLM Identifier NCT02204397 (accessed 8 May 2015). 31. National Institute of Allergy and Infectious Diseases, Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2014. Available from https://clinicaltrials.gov/ ct2/show/NCT02293837 NLM Identifier NCT02293837 (accessed 8 May 2015). 32. Louvet C, Szot GL, Lang J, Tyrosine kinase inhibitors reverse type 116 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 1 diabetes in nonobese diabetic mice, Proc Natl Acad Sci USA, 2008;105:18895–900. Huda MSB, Amiel SA, Ross P, Aylwin SJB, Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes, Diabetes Care, 2014;37:e87–e88. University of California, San Francisco, Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2013. Available at: https:// clinicaltrials.gov/ct2/show/NCT01781975 NLM Identifier NCT01781975 (accessed 8 May 2015). Ryba-Stanisławowska M, Rybarczyk-Kapturska K, My liwiec M, My liwska J, Elevated levels of serum IL-12 and IL-18 are associated with lower frequencies of CD4+CD25highFOXP3+ regulatory t cells in young patients with type 1 diabetes, Inflammation, 2014;37:1513–20. Haseda F, Imagawa A, Murase-Mishiba Y, et al., CD4+ CD45RA− FoxP3high activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes, Clin Exp Immunol, 2013;173: 207–16. Long SA, Cerosaletti K, Bollyky PL, et al., Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4+ CD25+ regulatory T-cells of type 1 diabetic subjects, Diabetes, 2010;59:407–15. Okubo Y, Torrey H, Butterworth J, Treg activation defect in type 1 diabetes: correction with TNFR2 agonism, Clin Transl Immunology, 2016;5:e56. Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children, Diabetes Care, 2012;35:1817–20. Bluestone JA, Buckner JH, Fitch M, Type 1 diabetes immunotherapy using polyclonal regulatory T cells, Sci Transl Med, 2015;7:315ra189. Bluestone JA, T1DM Immunotherapy Using Polyclonal Tregs + IL-2 (TILT). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2016. Available at: https://clinicaltrials.gov/ ct2/show/NCT02772679 NLM Identifier NCT02772679 (accessed 22 May 2016). Pabst O, Mowat AM, Oral tolerance to food protein, Mucosal Immunol, 2012;5:232–9. Skyler JS, Krischer JP, Wolfsdorf J, et al., Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial–Type 1, Diabetes Care, 2005;28:1068–76. Vehik K, Cuthbertson D, Ruhlig H, DPT-1 and TrialNet Study Groups, Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial, Diabetes Care, 2011;34:1585–90. National Institute of Diabetes and Digestive and Kidney Diseases, Oral insulin for prevention of diabetes in relatives at risk for type 1 diabetes mellitus. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2007. Available at: https:// 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. clinicaltrials .gov/ct2/show/NCT00419562 NLM Identifier: NCT00419562 (accessed 8 May 2016). Bonifacio E, Ziegler AG, Klingensmith G, et al., Effect of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial, JAMA, 2015;313:1541–9. National Institute of Diabetes and Digestive and Kidney Diseases, Exploring Immunologic Effects of Oral Insulin in Relatives at Risk for Type 1. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2007. Available at: https://clinicaltrials.gov / ct2/show/ NCT02580877 NLM Identifier: NCT02580877 (accessed 22 June 2016). Cardiff University, Phase 1b Study of Proinsulin (PI) Peptide Immunotherapy in New-Onset Type 1 Diabetes. In: ClinicalTrials. gov [Internet]. Bethesda, MD, National Library of Medicine, 2012. Available at: https://clinicaltrials.gov/ct2/show/NCT01536431 NLM Identifier: NCT01536431 (accessed 8 May 2016). Lund University, A Double-blind, Randomized Investigator-initiated Study to Determine the Safety and the Effect of Diamyd ® on the Progression to Type 1 Diabetes in Children With Multiple Islet Cell Autoantibodies. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2015. Available at: https:// clinicaltrials.gov/ct2/show/study/ NCT01122446 NLM Identifier: NCT01122446 (accessed 21 May 2016). Lund University, Double-blind, Investigator-initiated Study to Determine the Effect of Alum-GAD (Diamyd) in Combination With Vitamin D3 on the Progression to Type 1 Diabetes in Children With Multiple Islet Autoantibodies. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT02387164 NLM Identifier: NCT01536431 (accessed 8 May 2016). Voltarelli JC, Couri CE, Stracieri AB, et al., Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus, JAMA, 2007;297:1568– 76. Voltarelli JC, Martinez ED, Burt RK, Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus, JAMA, 2009;302:624–5. D’Addio F, Vasquez AV, Nasr MB, et al., Autologous nonmyeloablative , hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis, Diabetes, 2014;63:3041–6. Haller MJ, Gitelman SE, Gottlieb PA, et al., Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes, J Clin Invest, 2015;125 448–55. National Institute of Diabetes and Digestive and Kidney Diseases, Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2014. Available at: https://clinicaltrials.gov/ ct2/show/ NCT02215200 NLM Identifier: NCT02215200 (accessed 8 May 2016). US E ND OCRINOLOG Y